Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126855111 | 12685511 | 1 | I | 20150729 | 20160825 | 20160825 | PER | US-NOVOPROD-459102 | NOVO NORDISK | 59.00 | YR | A | F | Y | 0.00000 | 20160825 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126855111 | 12685511 | 1 | PS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 1.8 MG, QD | ES6P498 | 22341 | 1.8 | MG | SOLUTION FOR INJECTION | QD | |||||
126855111 | 12685511 | 2 | C | GLYBURIDE. | GLYBURIDE | 1 | Oral | 5 MG, BID | 0 | 5 | MG | BID | |||||||
126855111 | 12685511 | 3 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 1000 MG, BID | 0 | 1000 | MG | BID | |||||||
126855111 | 12685511 | 4 | C | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126855111 | 12685511 | 1 | Type 2 diabetes mellitus |
126855111 | 12685511 | 2 | Type 2 diabetes mellitus |
126855111 | 12685511 | 3 | Type 2 diabetes mellitus |
126855111 | 12685511 | 4 | Product used for unknown indication |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126855111 | 12685511 | Eructation | |
126855111 | 12685511 | Flatulence | |
126855111 | 12685511 | Muscle spasms |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |